sellWeak cluster of 210b5-1 plan
Kavita Patel sold $6.0M of ACLX
director at Arcellx, Inc.. 57,479 shares at an average of $103.90, traded Nov 7, 2024, filed Nov 12, 2024.
Warning score
33Value
$6.0M
57,479 shares
Holdings after
0
-678% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$6.0M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-026654, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2024 | MOption exercise Common Stock10b5-1 | +8,478 | $6.66 | $56k | 8,478 | Nov 12, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stock10b5-1 | -8,478 | $99.30 | $842k | 0 | Nov 12, 2024 |
| Nov 8, 2024 | MOption exercise Common Stock10b5-1 | +7,976 | $6.66 | $53k | 7,976 | Nov 12, 2024 |
| Nov 8, 2024 | MOption exercise Common Stock10b5-1 | +25,787 | $15.00 | $387k | 33,763 | Nov 12, 2024 |
| Nov 8, 2024 | SOpen-market sale Common Stock10b5-1 | -5,900 | $99.60 | $588k | 27,863 | Nov 12, 2024 |
| Nov 8, 2024 | SOpen-market sale Common Stock10b5-1 | -2,076 | $100.57 | $209k | 25,787 | Nov 12, 2024 |
| Nov 8, 2024 | SOpen-market sale Common Stock10b5-1 | -25,787 | $105.46 | $2.7M | 0 | Nov 12, 2024 |
| Nov 11, 2024 | MOption exercise Common Stock10b5-1 | +15,238 | $15.00 | $229k | 15,238 | Nov 12, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -12,233 | $105.68 | $1.3M | 3,005 | Nov 12, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -3,005 | $106.91 | $321k | 0 | Nov 12, 2024 |
| Nov 7, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -8,478 | $0.00 | $0 | 51,553 | Nov 12, 2024 |
| Nov 8, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -7,976 | $0.00 | $0 | 43,577 | Nov 12, 2024 |
| Nov 8, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -25,787 | $0.00 | $0 | 35,751 | Nov 12, 2024 |
| Nov 11, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -15,238 | $0.00 | $0 | 20,513 | Nov 12, 2024 |
Related signals
Other insiders at Arcellx, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $31k 340 shares | -54% | |
| 30Weak | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $488k 5,364 shares | -39% | |
| 38Weak | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $512k 5,946 shares | -30% | |
| 48Moderate | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $1.7M 21,034 shares | -97% | |
| 3Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $5,852 73 shares | -0% | |
| 38Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $993k 12,396 shares | -36% | |
| 9Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $291k 3,643 shares | -10% | |
| 18Weak | Arcellx, Inc. | Kavita Patel director | $101k 1,500 shares | -100% | |
| 47Moderate | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $785k 12,235 shares | -38% | |
| 17Weak | Arcellx, Inc. | Kavita Patel director | $88k 1,500 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.